GMAB vs HCSG: fair value comparison
Genmab A/S and Healthcare Services Group, Inc. · Updated 2026-09-12
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, HCSG currently sits closer to the top of our discount ranking.
| GMAB | HCSG | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $33.29 | $21.82 |
| 12-month range | $25.45–$33.29 | $16.25–$25.11 |
| Sector rank | #72 of 113 Healthcare | #70 of 113 Healthcare |
| Quality grade | D | D |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: GMAB fair value analysis · HCSG fair value analysis